Genmab preparing for busy 2018

Next year, Genmab expects to obtain an approval of the company’s prize asset Darzalex for first-line therapy of multiple myeloma and provide the first data in solid tumors during the summer. Moreover, the company’s pipeline is in for a busy year, when the number of clinical candidates will double from two to four and a potentially pivotal study of the leading candidate will be initiated.

Photo: Carsten Bundgaard

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

Omstridt parallelimportør går konkurs

Parallelimportøren Europharma, der to gange i 2017 blev suspenderet af Lægemiddelstyrelsen, er gået konkurs. Selskabet har erkendt, at et varelager for 50 mio. kr. er usælgeligt.

Related articles